Nirvana Sciences

NIRvana Sciences, founded in Durham, United States, is dedicated to enhancing medical diagnostics and imaging through the commercialization of novel fluorescent dyes with ultra-narrow emissions. Their core mission is to improve the performance of fluorescence-based medical diagnostic and imaging systems and tests. The company focuses on developing superior dyes for multiplexing in life science applications, working closely with corporate partners to bring their innovative solutions to market.

Notable achievements include being awarded a $1.65 million Phase 2 SBIR grant from the NIH, underscoring their impact and potential in the medical diagnostics field. The company's pioneering work with synthetic bacteriochlorins, which have significant ultraviolet absorption and near-infrared emissions, positions them as a leader in the development of advanced fluorescent dyes. Through these innovations, NIRvana Sciences is making significant strides in improving the accuracy and efficiency of medical diagnostics and imaging technologies.